1.88 (-%)
As of Dec 13, 2024
Source:
Rafael Holdings, Inc is a clinical stage biotechnology company dedicated to developing Trappsol Cyclo™, which is being evaluated in clinical trials for the potential treatment of Niemann-Pick Disease Type C1 (“NPC1”), a rare, fatal and progressive genetic disorder, a majority equity interest in LipoMedix Pharmaceuticals Ltd. (“LipoMedix”), a clinical stage pharmaceutical company, Barer Institute Inc. (“Barer”), a wholly-owned preclinical cancer metabolism research operation, and a majority interest in Cornerstone Pharmaceuticals, Inc.
Country | United States |
Headquarters | newark, new jersey |
Phone Number | 212-658-1450 |
Industry | finance |
CEO | William Conkling |
Website | www.rafaelholdings.com |